I was talking to my old postdoc advisor, Roger Fielding, who the human nutrition research

center on aging, the word sarcopenia came from there, right? It means poverty of flesh.

We were talking about GLP1 and his excitement for the research and all of his colleagues talking

about sarcopenia and GLP1s. And the reason why is very important, right? When people take these

medications, we see that they're losing a lot of weight. 20% of their total weight is being lost in a year, but we see that almost half of that weight

can come from muscle. To be fully transparent, the implications of that for strength and performance

and health span are not yet clear. But it still seems concerning, particularly if we think about

the population

who's taking these GLP-1 medications, most of them are 40, 50, 60 years of age, which is right

at the period where muscle loss is about to begin to accelerate. Throwing additional fuel on

that fire is not something we would want to do. Dr. Greg Grisicki. Kristen, so happy to be here. I Gersicki.

Kristen, so happy to be here.

I'm so pumped for this conversation.

We're going to dig into all things GLP1 receptors.

We recently published a paper, which you were the principal investigator and really the lead on that paper.

And it really is groundbreaking in a lot of ways. I think there's a lot

we don't know about these medications. And I think the more research that is done, the more we can

learn and the more we can use these medications responsibly, Just really grateful for you taking the lead and

your contributions in this space and so excited it again. First of all, you recently joined the

performance science team, so I could not be happier. But tell me, you know, what drew you to whoop?

Yeah, no, really dream come true, Kristen, and thank you so much. Couldn't be more

delighted to be here and work with you and the team. And I do want to say, though, maybe I was

...